Search for dissertations about: "rituximab"

Showing result 1 - 5 of 61 swedish dissertations containing the word rituximab.

  2. 1. Treatment with the monoclonal antibody rituximab in Multiple Sclerosis : a study based on an academic clinical trial

    Author : Pierre de Flon; Anders Svenningsson; Martin Gunnarsson; Katarina Laurell; Sten Fredrikson; Umeå universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Multiple sclerosis; Rituximab; Cytokines; Immunological profile; Neurofilament light; Treatment satisfaction; neurologi; Neurology;

    Abstract : Background: Multiple sclerosis (MS) is a chronic, inflammatory disease, affecting the central nervous system. A growing number of disease modifying treatment alternatives entails a need for an individualised risk-benefit- convenience analysis in the counselling of patients and methods to monitor the treatment effect, including markers for subclinical inflammation. READ MORE

  4. 2. Mantle cell lymphoma strategies in primary treatment

    Author : Alexandra Albertsson Lindblad; Tumörmikromiljö; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; mantle cell lymphoma; registry data; Clinical Trial; Phase I; Clinical Trial; Phase II; rituximab; bendamustine; lenalidomid; ibrutinib; ADCC; in vitro model; TP53 mutations; watchful waiting; mantle cell lymphoma; real-world data; lenalidomide; rituximab; bendamustin; ibrutinib; ADCC; TP53 mutation; CDKN2A; NGS; MIPI; Watchful waiting;

    Abstract : Mantle cell lymphoma (MCL) is associated with poor prognosis due to an aggressive clinical course. Being a rare disease, there are few randomized trials in MCL and there is no defined golden standard in primary treatment. READ MORE

  5. 3. Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms

    Author : Tove Wästerlid; Tumörmikromiljö; []
    Keywords : Burkitt Lymphoma; Chemotherapy; SOX11; Diffuse large B-cell lymphoma; Prognostic factors; Rituximab;

    Abstract : Burkitt lymphoma (BL) is a rare, aggressive disorder constituting 1% of all non-Hodgkin lymphoma. Diffuse large B-cell lymphoma (DLBCL) is more common, accounting for 30% of malignant lymphoma. Standard treatment for adult BL and for certain subgroups of patients with DLBCL remains to be defined due to paucity of randomised trials performed. READ MORE

  6. 4. Life and death of human B cells in health and disease

    Author : Andy Dernstedt; Mattias N. E. Forsell; Clas Ahlm; Jonas Klingström; Mats Bemark; Umeå universitet; []
    Keywords : NATURVETENSKAP; NATURAL SCIENCES; b cells; antibody; hantavirus; germinal centre; phagocytosis; selection; DAF; vaccination; rituximab;

    Abstract : B cells provide one of the key mechanisms of immunological memory, which is theproduction of neutralising antibodies. How B cells respond to infections and vaccinationgives clues to how the development of the immunological memory is facilitated, and canthus lead to a deeper understanding of why the immune system sometimesmalfunctions. READ MORE

  7. 5. Rituximab-induced neutropenia : clinical and patophysiological studies

    Author : Daniel Tesfa; Karolinska Institutet; Karolinska Institutet; []
    Keywords : ;

    Abstract : Rituximab is a monoclonal antibody directed against the CD20 antigen on normal and neoplastic B-lymphocytes. It was originally developed for treatment of lymphomas as a targeted therapy against CD20 positive non-Hodgkin lymphomas (NHL). More recently, its use has expanded into patients with rheumatic diseases. READ MORE